Trial record 3 of 6 for:    opt-80

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects

This study has been completed.
Sponsor:
Collaborator:
Optimer Pharmaceuticals
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )
ClinicalTrials.gov Identifier:
NCT01813448
First received: March 15, 2013
Last updated: May 23, 2013
Last verified: May 2013
  Purpose

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single and multiple ascending doses of fidaxomicin in healthy subjects. This study will also compare the safety, tolerability and PK of single and multiple doses of fidaxomicin in healthy Japanese and Caucasian subjects.


Condition Intervention Phase
Pharmacokinetics of Fidaxomicin
Healthy Subjects
Drug: Fidaxomicin
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Official Title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects

Resource links provided by NLM:


Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Pharmacokinetics (PK) of fidaxomicin in plasma (single dose): Lag time (tlag) [ Time Frame: Days 1-5 (14 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin plasma (single dose): Time to attain maximum concentration (tmax) [ Time Frame: Days 1-5 (14 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in plasma (single dose): Maximum Concentration (Cmax) [ Time Frame: Days 1-5 (14 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in plasma (single dose): Area Under the Plasma Concentration - Time Curve (AUC) from Time Zero to Time of Last Measurable Concentration (AUClast) [ Time Frame: Days 1-5 (14 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in plasma (single dose): AUC - Time Curve from Time Zero to Infinity (aucinf) [ Time Frame: Days 1-5 (14 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in plasma (single dose): AUC - Time Curve from Time Zero to 12 hours (AUC 0-12h) [ Time Frame: Days 1-5 (14 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in plasma (single dose): Total Body Clearance after Single Dose (CL/F) [ Time Frame: Days 1-5 (14 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in plasma (single dose): Apparent Volume of Distribution During Terminal Phase (Vz/F) [ Time Frame: Days 1-5 (14 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in plasma (last dose): Apparent Volume of Distribution During Terminal Phase (Vz/F) [ Time Frame: Days 15-17 (11 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in plasma (single dose): Apparent Terminal elimination Half-life (t 1/2) [ Time Frame: Days 1-5 (14 times) ] [ Designated as safety issue: No ]
    Single Dose

  • PK of fidaxomicin in plasma (last dose): Apparent Terminal elimination Half-life (t 1/2) [ Time Frame: Days 15-17 (11 times) ] [ Designated as safety issue: No ]
    Single Dose

  • PK of fidaxomicin in plasma (single dose): Trough levels [ Time Frame: Days 6, 7, 10, and 12 (pre-morning dose) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in plasma (last dose): tmax at Steady State (tmax, ss) [ Time Frame: Days 15-17 (11 times) ] [ Designated as safety issue: No ]
    Last Dose

  • PK of fidaxomicin in plasma (last dose): Cmax at Steady State (Cmax, ss) [ Time Frame: Days 15-17 (11 times) ] [ Designated as safety issue: No ]
    Last Dose

  • PK of fidaxomicin in plasma (last dose): AUC Over the dosing Interval (AUCtau) [ Time Frame: Days 15-17 (11 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in plasma (last dose): CL/F at Steady State (CL/F ss) [ Time Frame: Days 15-17 (11 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in plasma (last dose): Peak: Trough Ratio (PTR) [ Time Frame: Days 15-17 (11 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in plasma (last dose): Accumulation Ratio (Racc) [ Time Frame: Days 15-17 (11 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in plasma (last dose): Pre-dose Plasma Concentration Determined Directly from the Concentration-Time Profile (Ctrough) [ Time Frame: Days 15-17 (11 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in urine (last dose): Cumulative Amount of Drug Excreted in the urine from Time Zero to Time of Last Measurable Concentration (Aelast) [ Time Frame: Days 1-5 (6 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in urine (single dose): Percent Fraction of Administered Drug Excreted Unchanged in the urine from Time Zero to Time of Last Measurable Concentration (% Aelast ) [ Time Frame: Days 1-5 (6 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in urine (single dose): Cumulative Amount of Drug Excreted in the Urine from time Zero to Infinity after Single Dose (Aeinf) [ Time Frame: Days 1-5 (6 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in urine (single dose): Percent Fraction of administered drug excreted unchanged in the urine from time Zero to Infinity after Single Dose (% Aeinf) [ Time Frame: Days 1-5 (6 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in urine (single dose): Renal Clearance (CL/R [ Time Frame: Days 1-5 (6 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in urine (last dose): Cumulative Amount of Drug Excreted in the urine over the dosing Interval at Steady State (Aetau) [ Time Frame: Day 15 (1 time) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in urine (last dose): Percent Fraction of Administered Drug Excreted Unchanged in the Urine over the Dosing Interval at Steady State (% Aetau) [ Time Frame: Day 15 (1 time) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in urine (last dose): Renal Clearance at Steady State (CLR,ss) [ Time Frame: Day 15 ( 1 time) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in feces (single dose): Amount of Drug Excreted in the Feces (Ae) [ Time Frame: Days 1-5 (5 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in feces (last dose): Amount of Drug Excreted in the Feces (Ae) [ Time Frame: Days 15-17 (first bowel movement (BM) following the last dose to be collected) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in feces (single dose): Percent Fraction of Administered Drug Excreted Unchanged in the Feces (%Ae) [ Time Frame: Days 1-5 (5 times) ] [ Designated as safety issue: No ]
  • PK of fidaxomicin in feces (last dose): Percent Fraction of Administered Drug Excreted Unchanged in the Feces (%Ae) [ Time Frame: Days 15-17 (first BM following the last dose to be collected) ] [ Designated as safety issue: No ]

Enrollment: 36
Study Start Date: February 2013
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1: Fidaxomicin low dose in Japanese males Drug: Fidaxomicin
oral
Other Name: OPT-80
Experimental: Cohort 2: Fidaxomicin high dose in Japanese males Drug: Fidaxomicin
oral
Other Name: OPT-80
Experimental: Cohort 3: Fidaxomicin high dose in Caucasian males Drug: Fidaxomicin
oral
Other Name: OPT-80
Placebo Comparator: Matching Placebo in Caucasian males Drug: Placebo
oral
Placebo Comparator: Matching Placebo in Japanese males Drug: Placebo
oral

Detailed Description:

Eligible subjects will check into the unit on Day-2 and remain confined to the clinical unit until Day 17.

Cohorts 2 and 3, which may run in parallel, will only be enrolled after review of the available safety data of Cohort 1 by the Safety Review Team.

  Eligibility

Ages Eligible for Study:   20 Years to 55 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continuing throughout the study period and for 90 days after final study drug administration
  2. Male subject must not donate sperm starting at Screening and throughout the study period and for at least 90 days after final study drug administration

    Inclusion Criteria for Japanese Subjects

  3. The subject is a healthy Japanese male who maintains the Japanese lifestyle, including diet and has a body mass index (BMI) of 18.0 to 28.0 kg/m2, inclusive.

    Inclusion Criteria for Caucasian Subjects

  4. The subject is a healthy Caucasian male and has a BMI of 18.0 to 32.0 kg/m2, inclusive

Exclusion Criteria:

  1. The subject has any clinically significant disease history
  2. The subject has a history of or current C.difficile infection or history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (history of appendectomy, hernia repair, and/or cholecystectomy is permitted)
  3. The subject has any clinically significant abnormality
  4. The subject has a resting (i.e., seated for 5 minutes) pulse <40 or >90 beats per minute (bpm) at Screening or Day -2
  5. The subject has hypertension (defined as seated systolic blood pressure [SBP] >140 mmHg or seated diastolic blood pressure [DBP] >90 mmHg) or hypotension (defined as seated SBP <90 mmHg or seated DBP <50 mmHg) at Screening or Day -2
  6. The subject has/had a symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to clinic check-in on Day -2
  7. The subject has a history of chronic diarrhea or constipation
  8. The subject has a positive result for hepatitis C antibodies or hepatitis B surface antigen at Screening or has a known positive history of human immunodeficiency virus (HIV)
  9. The subject has a known or suspected allergy or hypersensitivity to any of the components of fidaxomicin, the macrolide antibacterial class of compounds, or a history of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reactions
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01813448

Locations
United States, California
Parexel
Glendale, California, United States, 91206
Sponsors and Collaborators
Astellas Pharma Global Development, Inc.
Optimer Pharmaceuticals
Investigators
Study Director: Sr. Medical Director Astellas Pharma Global Development, Inc.
  More Information

No publications provided

Responsible Party: Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )
ClinicalTrials.gov Identifier: NCT01813448     History of Changes
Other Study ID Numbers: 2819-CL-3001
Study First Received: March 15, 2013
Last Updated: May 23, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Astellas Pharma Inc:
Fidaxomicin
OPT-80
Healthy Subjects

ClinicalTrials.gov processed this record on April 15, 2014